APEPTICO - Innovation in peptide drugs - SOLNATIDE Compassionate Use Program

SOLNATIDE IMP has been authorised for Compassionate Use for the treatment of severe COVID-19 patients in Austria and Italy

Clinical use of SOLNATIDE during the Compassionat Use programe

The patient described below has been treated with Solnatide IMP within the Compassionate Use Program in Austria at the clinics Klagenfurt am Wörthersee, Department of Anaesthesiology and Intensive Care, during treatment of COVID-19 and prior LTX.